FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma

Previous reports suggest a correlation between positron emission tomography with fluorodeoxyglucose maximum standardized uptake value (SUVmax) and epidermal growth factor receptor (EGFR) mutation status in lung cancer. We analysed positron emission tomography with fluorodeoxyglucose SUVmax in 14 pat...

Full description

Saved in:
Bibliographic Details
Published inRespirology (Carlton, Vic.) Vol. 18; no. 4; pp. 734 - 735
Main Authors Putora, Paul M., Früh, Martin, Müller, Joachim
Format Journal Article
LanguageEnglish
Published Australia Blackwell Publishing Ltd 01.05.2013
Subjects
Adenocarcinoma - genetics
Adenocarcinoma - metabolism
Adenocarcinoma - pathology
Case-Control Studies
Cell Proliferation
epidermal growth factor receptor
Fluorodeoxyglucose F18 - metabolism
genetic association
Genotype
Humans
imaging
lung cancer
Lung Neoplasms - genetics
Lung Neoplasms - metabolism
Lung Neoplasms - pathology
Mutation - genetics
Positron-Emission Tomography - methods
Predictive Value of Tests
primary tumour standardized uptake
Receptor, Epidermal Growth Factor - genetics
Survival Rate
Online AccessGet full text

Cover

Abstract Previous reports suggest a correlation between positron emission tomography with fluorodeoxyglucose maximum standardized uptake value (SUVmax) and epidermal growth factor receptor (EGFR) mutation status in lung cancer. We analysed positron emission tomography with fluorodeoxyglucose SUVmax in 14 patients with EGFR mutations, and a control group of 14 subjects with wild‐type EGFR adenocarcinomas. The mean SUV value was 10.7 for EGFR‐mutated adenocarcinomas and 9.9 for wild‐type tumours. There was no correlation between SUV values and EGFR mutation status. Omitting EGFR testing in lung cancers with low SUVmax is not appropriate.
AbstractList Previous reports suggest a correlation between positron emission tomography with fluorodeoxyglucose maximum standardized uptake value (SUVmax) and epidermal growth factor receptor (EGFR) mutation status in lung cancer. We analysed positron emission tomography with fluorodeoxyglucose SUVmax in 14 patients with EGFR mutations, and a control group of 14 subjects with wild-type EGFR adenocarcinomas. The mean SUV value was 10.7 for EGFR-mutated adenocarcinomas and 9.9 for wild-type tumours. There was no correlation between SUV values and EGFR mutation status. Omitting EGFR testing in lung cancers with low SUVmax is not appropriate.Previous reports suggest a correlation between positron emission tomography with fluorodeoxyglucose maximum standardized uptake value (SUVmax) and epidermal growth factor receptor (EGFR) mutation status in lung cancer. We analysed positron emission tomography with fluorodeoxyglucose SUVmax in 14 patients with EGFR mutations, and a control group of 14 subjects with wild-type EGFR adenocarcinomas. The mean SUV value was 10.7 for EGFR-mutated adenocarcinomas and 9.9 for wild-type tumours. There was no correlation between SUV values and EGFR mutation status. Omitting EGFR testing in lung cancers with low SUVmax is not appropriate.
Previous reports suggest a correlation between positron emission tomography with fluorodeoxyglucose maximum standardized uptake value (SUVmax) and epidermal growth factor receptor (EGFR) mutation status in lung cancer. We analysed positron emission tomography with fluorodeoxyglucose SUVmax in 14 patients with EGFR mutations, and a control group of 14 subjects with wild‐type EGFR adenocarcinomas. The mean SUV value was 10.7 for EGFR‐mutated adenocarcinomas and 9.9 for wild‐type tumours. There was no correlation between SUV values and EGFR mutation status. Omitting EGFR testing in lung cancers with low SUVmax is not appropriate.
Previous reports suggest a correlation between positron emission tomography with fluorodeoxyglucose maximum standardized uptake value ( SUV max) and epidermal growth factor receptor ( EGFR ) mutation status in lung cancer. We analysed positron emission tomography with fluorodeoxyglucose SUV max in 14 patients with EGFR mutations, and a control group of 14 subjects with wild‐type EGFR adenocarcinomas. The mean SUV value was 10.7 for EGFR ‐mutated adenocarcinomas and 9.9 for wild‐type tumours. There was no correlation between SUV values and EGFR mutation status. Omitting EGFR testing in lung cancers with low SUV max is not appropriate.
Author Putora, Paul M.
Früh, Martin
Müller, Joachim
Author_xml – sequence: 1
  givenname: Paul M.
  surname: Putora
  fullname: Putora, Paul M.
  email: paul.putora@kssg.ch
  organization: Department of Radiation Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland
– sequence: 2
  givenname: Martin
  surname: Früh
  fullname: Früh, Martin
  organization: Department of Haematology and Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland
– sequence: 3
  givenname: Joachim
  surname: Müller
  fullname: Müller, Joachim
  organization: Department of Nuclear Medicine, Kantonsspital St. Gallen, St. Gallen, Switzerland
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23489365$$D View this record in MEDLINE/PubMed
BookMark eNp9kU1v1DAQhi1URL-48AOQjwgpxY7tfBzRsl2QKlr182h5nXExJHZqO2z77_GStocK4cuMrOcZaebdRzvOO0DoHSVHNL9PAeJ4REvSsFdoj3JOCtpwtpN7VrKirtt2F-3H-JMQwgQRb9BuyXjTskrsoXT8ZVWcLS_xxdV1Mah7_Fv1E0Tceex8wtqHAL1KgDc2_cAw2g7CoHp8G_wmfxilkw84gIZx2wxTUsl6h2OuU8TW4X5yt1h14LxWQVvnB3WIXhvVR3j7WA_Q1fHycvG1ODldfVt8Pik0J4wVJSFck8asVWWajilBdEmhbg2YyhhhYC14SzLBdNV2XItatMSUHSEd5Zqv2QH6MM8dg7_LWyU52Kih75UDP0VJGa9EU9YNzej7R3RaD9DJMdhBhQf5dKkMfJwBHXyMAcwzQoncxiC3Mci_MWSYvIC1nQ-TgrL9vxU6Kxvbw8N_hsvz5cXZk1PMjo0J7p8dFX7Jqma1kDffV3Jx3bDyhi7kiv0BFBGqWQ
CitedBy_id crossref_primary_10_1080_08941939_2023_2301081
crossref_primary_10_2174_1874471013666191223151402
crossref_primary_10_1097_RLU_0000000000000975
crossref_primary_10_3892_ijo_2018_4626
crossref_primary_10_1007_s11604_022_01347_1
crossref_primary_10_2147_CMAR_S259055
crossref_primary_10_3389_fonc_2019_01062
crossref_primary_10_1016_j_cpet_2017_09_006
crossref_primary_10_1111_resp_12250
crossref_primary_10_18632_oncotarget_24893
crossref_primary_10_1007_s13139_014_0283_3
crossref_primary_10_1007_s13139_020_00646_7
crossref_primary_10_1088_1361_6560_aad648
crossref_primary_10_1097_MNM_0000000000001076
crossref_primary_10_18632_oncotarget_16806
crossref_primary_10_1186_s12885_016_2251_z
crossref_primary_10_1007_s00432_013_1545_7
crossref_primary_10_1007_s13139_016_0453_6
crossref_primary_10_2147_IJGM_S287506
crossref_primary_10_1159_000450622
Cites_doi 10.1634/theoncologist.2010-0300
10.1016/j.lungcan.2009.03.010
10.1055/s-0032-1302854
10.1016/S1010-7940(00)00535-2
10.1007/s12032-008-9160-1
10.1016/S1470-2045(04)01564-5
ContentType Journal Article
Copyright 2013 The Authors. Respirology © 2013 Asian Pacific Society of Respirology
2013 The Authors. Respirology © 2013 Asian Pacific Society of Respirology.
Copyright_xml – notice: 2013 The Authors. Respirology © 2013 Asian Pacific Society of Respirology
– notice: 2013 The Authors. Respirology © 2013 Asian Pacific Society of Respirology.
DBID BSCLL
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1111/resp.12083
DatabaseName Istex
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

CrossRef
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1440-1843
EndPage 735
ExternalDocumentID 23489365
10_1111_resp_12083
RESP12083
ark_67375_WNG_CV832W1C_G
Genre letter
Letter
Evaluation Studies
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
123
1OB
1OC
29P
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AHEFC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
AOETA
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EJD
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
KBYEO
KMS
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
TEORI
UB1
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOQ
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
YFH
ZZTAW
~IA
~WT
AAHQN
AAIPD
AAMNL
AANHP
AAYCA
ACRPL
ACYXJ
ADNMO
AFWVQ
ALVPJ
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c4033-2004c08fba6f8d3a50c21e79fef6ff5feb5490c083c69d4c57590f2d00d14c4b3
IEDL.DBID DR2
ISSN 1323-7799
1440-1843
IngestDate Thu Jul 10 20:16:00 EDT 2025
Mon Jul 21 05:42:00 EDT 2025
Thu Apr 24 22:51:41 EDT 2025
Tue Jul 01 02:00:23 EDT 2025
Wed Jan 22 16:36:26 EST 2025
Wed Oct 30 09:57:16 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
2013 The Authors. Respirology © 2013 Asian Pacific Society of Respirology.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4033-2004c08fba6f8d3a50c21e79fef6ff5feb5490c083c69d4c57590f2d00d14c4b3
Notes ArticleID:RESP12083
ark:/67375/WNG-CV832W1C-G
istex:FFF9BE36120EBC863796F5500982699458A23B73
SourceType-Scholarly Journals-1
ObjectType-Correspondence-2
ObjectType-Undefined-1
content type line 23
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/resp.12083
PMID 23489365
PQID 1346582781
PQPubID 23479
PageCount 2
ParticipantIDs proquest_miscellaneous_1346582781
pubmed_primary_23489365
crossref_primary_10_1111_resp_12083
crossref_citationtrail_10_1111_resp_12083
wiley_primary_10_1111_resp_12083_RESP12083
istex_primary_ark_67375_WNG_CV832W1C_G
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate May 2013
PublicationDateYYYYMMDD 2013-05-01
PublicationDate_xml – month: 05
  year: 2013
  text: May 2013
PublicationDecade 2010
PublicationPlace Australia
PublicationPlace_xml – name: Australia
PublicationTitle Respirology (Carlton, Vic.)
PublicationTitleAlternate Respirology
PublicationYear 2013
Publisher Blackwell Publishing Ltd
Publisher_xml – name: Blackwell Publishing Ltd
References Förster GJ, Misch D, Kollmeier J et al. Der SUV im FDG-PET als prädiktiver Wert einer EGFR-Mutation beim nicht-kleinzelligen Lungenkarzinom. Pneumologie 2012; 66: P201.
Huang CT, Yen RF, Cheng MF et al. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. Med. Oncol. 2010; 27: 9-15.
Na II, Byun BH, Kim KM et al. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis. Lung Cancer 2010; 67: 6-80.
Mak RH, Digumarthy SR, Muzikansky A et al. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. Oncologist 2011; 16: 19-26.
Vansteenkiste J, Fischer BM, Dooms C et al. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol. 2004; 5: 31-40.
Dhital K, Saunders CA, Seed PT et al. [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur. J. Cardiothorac. Surg. 2000; 18: 25-28.
2010; 67
2011; 16
2004; 5
2012; 66
2010; 27
2000; 18
e_1_2_3_2_1
e_1_2_3_7_1
e_1_2_3_6_1
e_1_2_3_5_1
e_1_2_3_4_1
e_1_2_3_3_1
References_xml – reference: Na II, Byun BH, Kim KM et al. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis. Lung Cancer 2010; 67: 6-80.
– reference: Förster GJ, Misch D, Kollmeier J et al. Der SUV im FDG-PET als prädiktiver Wert einer EGFR-Mutation beim nicht-kleinzelligen Lungenkarzinom. Pneumologie 2012; 66: P201.
– reference: Huang CT, Yen RF, Cheng MF et al. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. Med. Oncol. 2010; 27: 9-15.
– reference: Mak RH, Digumarthy SR, Muzikansky A et al. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. Oncologist 2011; 16: 19-26.
– reference: Vansteenkiste J, Fischer BM, Dooms C et al. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol. 2004; 5: 31-40.
– reference: Dhital K, Saunders CA, Seed PT et al. [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur. J. Cardiothorac. Surg. 2000; 18: 25-28.
– volume: 66
  start-page: P201
  year: 2012
  article-title: Der SUV im FDG‐PET als prädiktiver Wert einer EGFR‐Mutation beim nicht‐kleinzelligen Lungenkarzinom
  publication-title: Pneumologie
– volume: 5
  start-page: 31
  year: 2004
  end-page: 40
  article-title: Positron‐emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review
  publication-title: Lancet Oncol.
– volume: 67
  start-page: 6
  year: 2010
  end-page: 80
  article-title: 18F‐FDG uptake and EGFR mutations in patients with non‐small cell lung cancer: a single‐institution retrospective analysis
  publication-title: Lung Cancer
– volume: 16
  start-page: 19
  year: 2011
  end-page: 26
  article-title: Role of 18F‐fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non‐small cell lung cancer
  publication-title: Oncologist
– volume: 18
  start-page: 25
  year: 2000
  end-page: 28
  article-title: [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer
  publication-title: Eur. J. Cardiothorac. Surg.
– volume: 27
  start-page: 9
  year: 2010
  end-page: 15
  article-title: Correlation of F‐18 fluorodeoxyglucose‐positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma
  publication-title: Med. Oncol.
– ident: e_1_2_3_5_1
  doi: 10.1634/theoncologist.2010-0300
– ident: e_1_2_3_3_1
  doi: 10.1016/j.lungcan.2009.03.010
– ident: e_1_2_3_2_1
  doi: 10.1055/s-0032-1302854
– ident: e_1_2_3_7_1
  doi: 10.1016/S1010-7940(00)00535-2
– ident: e_1_2_3_4_1
  doi: 10.1007/s12032-008-9160-1
– ident: e_1_2_3_6_1
  doi: 10.1016/S1470-2045(04)01564-5
SSID ssj0003505
Score 2.1169987
Snippet Previous reports suggest a correlation between positron emission tomography with fluorodeoxyglucose maximum standardized uptake value (SUVmax) and epidermal...
Previous reports suggest a correlation between positron emission tomography with fluorodeoxyglucose maximum standardized uptake value ( SUV max) and epidermal...
SourceID proquest
pubmed
crossref
wiley
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 734
SubjectTerms Adenocarcinoma - genetics
Adenocarcinoma - metabolism
Adenocarcinoma - pathology
Case-Control Studies
Cell Proliferation
epidermal growth factor receptor
Fluorodeoxyglucose F18 - metabolism
genetic association
Genotype
Humans
imaging
lung cancer
Lung Neoplasms - genetics
Lung Neoplasms - metabolism
Lung Neoplasms - pathology
Mutation - genetics
Positron-Emission Tomography - methods
Predictive Value of Tests
primary tumour standardized uptake
Receptor, Epidermal Growth Factor - genetics
Survival Rate
Title FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma
URI https://api.istex.fr/ark:/67375/WNG-CV832W1C-G/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fresp.12083
https://www.ncbi.nlm.nih.gov/pubmed/23489365
https://www.proquest.com/docview/1346582781
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ta9RAEF5KBfGL1tfGqqwogkKOJLubF_CLnL0rQkvRXtsvEvZVpHfJcXeBw0_-BH-jv8SZTXK1UgT9toRJstnMzD6zOzsPIS-d0ylMazI0LpIhl3ka5kbZkIvCZC53rmB4OPnwKD2Y8A_n4nyLvO3PwrT1ITYLbmgZ3l-jgUu1_M3IIRqdD-IEIAQ4YEzWQkT08bJ2FBM-fxGiLQYQsii62qSYxnN565XZ6AYO7Po6qHkVufqpZ3SHfO473WacXAyalRrob3_Uc_zfr9ohtztMSt-1SnSXbNnqHrl52O263yfr0fvxz-8_jvdP6KfJKbRmck2xSrhdUlPTql5RjSQfU8CtFBd2qUXeWXD5U_oFwny40NL6UHCvdo6NWdOmAFA80NQs6deKTsHtUAluEGbXBby4nskHZDLaPxkehB1jQ6i5J4UDk9NR7pRMXW6YFJFOYpsVzrrUOeGsgnA0Agmm08JwjeygkUtMFJmYa67YQ7Jd1ZXdJZRFTmmT2FxDxOaEhchL24LFQjGjuc4C8rr_c6Xuypkjq8a07MMaHMrSD2VAXmxk520Rj2ulXnkF2IjIxQWmvWWiPDsal8NTcH5n8bAcB-R5ryElGCPusMjK1s2yjBkHRJdkeRyQR63qbJ6WMKzzk4qAvPEK8JeelGB8x771-F-E98itxJN1YDrmE7K9WjT2KUCmlXrmTeMXLCkVqg
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ZbtNAFB1BKwEv7ItZB4GQQHJkezxeHlFoEqCJKkjavo3Gs1RVEztKYiniiU_gG_kS7h07KUUVEryNrOttfNfxnXMIeW2tSiCsSV_bQPqxzBI_04XxY57r1GbW5gw3Jw9HyWASfzrmx21vDu6FafAhtgtuaBnOX6OB44L0b1YO5ei8E0aQQ1wlu0jp7SqqL-foUYy7DkaotxgkkXneopNiI8_5uRfi0S5O7fqyZPNi7uqCT-9Ww7C6dJiF2HNy1qlXRUd9-wPR8b_f6za52aal9H2jR3fIFVPeJdeG7Y_3e2Td-9D_-f3Hwd6Yfp0cwmgm1xSBws2S6oqW1Yoq5PmYQupKcW2XGqSeBa8_pSdQ6cOBhtmHgoc1cxzM6qYLgOKepnpJT0s6Bc9DJXhCCLALuHE1k_fJpLc37g78lrTBV7HjhQOrU0FmC5nYTDPJAxWFJs2tsYm13JoCKtIAJJhKch0rJAgNbKSDQIexigv2gOyUVWkeEcoCWygdmUxB0Wa5geJLmZyFvGBaxSr1yNvNpxOqRTRHYo2p2FQ2OJXCTaVHXm1l5w2Ox6VSb5wGbEXk4gw731IujkZ90T0E_3cUdkXfIy83KiLAHvEniyxNVS9FyEAVsyjNQo88bHRne7WIIdRPwj3yzmnAX55EgP0duNHjfxF-Qa4PxsN9sf9x9PkJuRE57g7sznxKdlaL2jyDDGpVPHd28gtl1hnF
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Za9tAEB7SBEJfeh_quaWl0IKMpF1d0Jdix06PGNPGSV7CstqjlNiysS0wfepP6G_sL-nsSnKaEgrt2yJG0mo1MzuzO_t9AC-MkQlOa8JXJhA-E1niZ6rQPotzlZrMmJzaw8kHw2R_zN6fxCdb8KY9C1PjQ2wW3KxlOH9tDXyuzG9GjtnovBNGGEJcgR2WBJnV6d6nc_AoGrsCRky3KMaQed6Ak9o6nvN7L0xHO3Zk15fFmhdDVzf39K_DadvruuTkrFOtio789geg4_9-1g241gSl5G2tRTdhS5e3YPeg2Xa_Det-b_Dz-4_R3iH5PD7C1lSsiYUJ10uiZqScrYi0LB8TDFyJXdkl2hLPos-fkC-Y5-OFmteHoH_Vc9uYVnUNALEnmqol-VqSCfodItAP4vS6wBfPpuIOjPt7h919v6Fs8CVzrHBoczLITCESkykq4kBGoU5zo01iTGx0gflogBJUJrli0tKDBiZSQaBCJllB78J2OSv1fSA0MIVUkc4kpmwm1ph6SZ3TMC6okkymHrxq_xyXDZ65pdWY8DavsUPJ3VB68HwjO69RPC6VeukUYCMiFme27i2N-fFwwLtH6P2Owy4fePCs1RCO1mi3WESpZ9WSh5RhSBelWejBvVp1Nk-LqAX6SWIPXjsF-EtPOFrfyLUe_IvwU9gd9fr847vhh4dwNXLEHbY08xFsrxaVfozh06p44qzkFy9PGH0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=FDG-PET+SUV-max+values+do+not+correlate+with+epidermal+growth+factor+receptor+mutation+status+in+lung+adenocarcinoma&rft.jtitle=Respirology+%28Carlton%2C+Vic.%29&rft.au=Putora%2C+Paul+M&rft.au=Fr%C3%BCh%2C+Martin&rft.au=M%C3%BCller%2C+Joachim&rft.date=2013-05-01&rft.issn=1440-1843&rft.eissn=1440-1843&rft.volume=18&rft.issue=4&rft.spage=734&rft_id=info:doi/10.1111%2Fresp.12083&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1323-7799&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1323-7799&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1323-7799&client=summon